ClinicalTrials.gg
CompletedNCT02597634DOMSUpdated Oct 13, 2016

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

A Phase 3 interventional study of SST-0225 and Placebo in Delayed Onset Muscle Soreness, DOMS, sponsored by Strategic Science & Technologies, LLC. Completed at 3 sites in United States. Open to participants aged 16 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-13.

Sponsored by Strategic Science & Technologies, LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Myalgia with a site in United States — 13 open to participants now, 15 under way, none of them phase 3. Myalgia · United States.

Enrollment
10th of 77
156 · median 40
Started
2015
with 4 others
Phase 3
8 of 86
none open now
Registered
31st of 86
by date

Among the 86 studies in Myalgia with a site in United States, this one is the 10th largest by enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2015, is one of 8 in phase 3, and was the 31st registered.

Myalgia

256 studies on the registry are indexed under Myalgia; 46 are open to participants now.

Browse Myalgia studies →

Open to participants now

13 of the 86 studies in Myalgia with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Myalgia studies recruiting now, 6 (22%) set no upper age limit and 20 (74%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Myalgia with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, prospective, randomized, dual-center, double-blind, placebo-controlled, parallel-group study designed to determine the efficacy and safety of SST-0225 (5.4 grams, applied up to 6 times in 24 hours, over a 48-hour dosing period) for the treatment of pain associated with DOMS.

Read the detailed description

This is a Phase 3, prospective, randomized, multicenter, double blind, placebo controlled, parallel group study designed to determine the efficacy and safety of SST-0225 for the treatment of pain associated with DOMS. Healthy volunteers will be recruited to undergo an exercise regimen designed to induce DOMS in the elbow flexor of the non-dominant arm. Subjects who are eligible following the exercise regimen will be randomized to receive treatment with SST-0225 or placebo for a 48 hour period. Subjects will be housed in the clinic for the first 24 hours of dosing and sent home for the second 24 hour dosing period. Arm pain/soreness will be assessed throughout the study using an 11-point (0-10) Numeric Rating Scale (NRS).

Approximately 150 subjects will be randomized in a 1:1 ratio to SST-0225 or placebo at up to three study centers in the US. Subject participation will be between 12 and 26 days depending on the length of the initial screening period. Once a subject is randomized the duration of participation will be 10 days. The expected duration of the study is approximately six months depending on enrollment. The sample size may be increased to a maximum of 250 based on the results of the planned interim analysis described in Section 15.2 of the protocol.

03

Conditions studied

  • Delayed Onset Muscle Soreness, DOMS

Browse trials for

04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria The following inclusion criteria will be assessed from the Screening Visit up to the time of randomization:

  1. Men and women age 16-65, inclusive
  2. Subjects must be able to read, understand, sign, and date the /assent document indicating they (or a legally acceptable representative) have been informed of all pertinent aspects of the trial
  3. Female subjects must agree to use medically acceptable methods from the Screening Visit (unless otherwise stated) through end of study (EOS).
  4. Subjects must be able to speak, read, and comprehend English or Spanish, and complete required measurements as outlined in the protocol
  5. Subjects must agree to refrain from upper body resistance training and any unusual or excessive exercise during the screening period and for the duration of the study, including follow-up
  6. Subjects must agree to refrain from the use of restricted therapies during the screening period and until the completion of the dosing period

Key Exclusion Criteria The following exclusion criteria will be assessed from the Screening Visit up to the time of randomization.

  1. Subjects who have had an injury to the non-dominant arm such as adhesive capsulitis, bursitis, rotator cuff syndrome, within the six months prior to the Screening Visit
  2. Subjects with medial or lateral epicondylitis (tennis elbow) of the non-dominant arm
  3. Subjects who have an open wound, skin irritation, or infection on the non-dominant arm in the area to be treated
  4. Subjects who have engaged in any upper body resistance training in the six months prior to the Screening Visit
  5. Subjects who are actively engaged in manual or physical labor jobs (i.e. brick layer, construction worker, carpenter, house painter)
  6. Subjects who should not participate in strenuous exercise for medical reasons
  7. Subjects who have abnormal laboratory parameters at the Screening Visit that, in the opinion of the Investigator, could confound interpretation of the study results
  8. Subjects with an abnormal physical exam that, in the opinion of the Investigator, would interfere with study participation
  9. Subjects who have received oral or injectable systemic within three months prior to the Screening Visit
  10. Subjects with osteoarthritis of the hands, fingers, elbows, or shoulders
  11. Subjects with chronic pain
  12. Subjects with an allergy or a history of allergy or intolerance to aspirin, NSAIDs, acetaminophen or any of the in the IP (L-arginine hydrochloride, glyceryl stearate, cetyl alcohol, squalane, xanthan gum, isopropyl myristate, oleic acid, propylene glycol, polysorbate 20, methyl paraben, phenoxyethanol, propyl paraben, dimethicone)
  13. Subjects with current viral or bacterial infections
  14. Subjects with certain medical conditions, including:

    1. Peptic ulcer disease
    2. Fibromyalgia
    3. gastrointestinal, renal, or hepatic disease within the past six months, in the opinion of the Investigator
    4. Clinically significant cardiovascular disease, in the opinion of the Investigator, not stable for the past six months
    5. Uncontrolled hypertension as indicated by systolic blood pressure ≥ 160 mmHg or a diastolic blood pressure ≥ 100 mmHg
    6. Coagulation disorders or hematologic disease
    7. History of seizures
    8. Known, significant, pre-existing conditions that in the opinion of the Investigator would affect the interpretation of any study data.
  15. Subjects with certain myopathies or metabolic defects, including:

    1. Polymyositis (inflammatory)
    2. Sickle cell trait (genetic)
    3. Lipid metabolism disorders (carnitine deficiency, carnitine palmitoyl transferase [CPT] deficiency, β-oxidation enzyme defects)
    4. Glucose metabolism disorders (phosphorylase deficiency [McArdle's Disease], glycolysis enzyme defects).
  16. Subjects who have taken anticoagulants, angiotensin-converting enzyme inhibitors, lithium or methotrexate within 30 days prior to the Screening Visit
  17. Subjects who are currently taking tricyclic antidepressants including, but not limited to the following:

    1. amitriptyline
    2. clomipramine (Anafranil™)
    3. doxepin (Sinequan®)
    4. imipramine (Tofranil™)
    5. trimipramine (Surmontil®)
    6. amoxapine (Amoxapine Tablets)
    7. desipramine (Norpramin®)
    8. nortriptyline (Pamelor™)
    9. protriptyline (Vivactil®)
  18. Subjects with known alcohol abuse, drug dependency, or history of significant psychiatric illness within the past 12 months prior to the Screening Visit
  19. Subjects who have used an drug within 30 days prior to the Screening Visit
  20. Subjects who are taking diuretics, statins, cyclosporine, or colchicine
  21. Subjects with a positive drug screen
  22. Females who are pregnant or lactating
  23. Subjects who are color-blind
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    SST-0225

    Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.

    Drug: SST-0225

  • Placebo comparator
    Placebo

    Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.

    Drug: Placebo

Interventions

  • DrugSST-0225

    SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.

    Also known as: Topical Ibuprofen Cream

  • DrugPlacebo

    Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.

    Also known as: Placebo Cream

06

What researchers measure

Primary outcomes

  1. SPID24 (calculated by summing the time weighted NRS pain/soreness on movement assessment differences from baseline)

    The primary efficacy endpoint will be the time weighted summed pain/soreness intensity difference from baseline NRS pain/soreness on movement assessments over the first 24 hours (SPID24) following the first application of IP on Day 1. SPID24 will be calculated by summing the time weighted NRS pain/soreness on movement assessment differences from baseline (pre-dose on Day 1) to 24 hours (using actual reported NRS assessment times) post first dose of IP on Day 1.

    Time frame: First 24 hours after first dose

07

Study locations

3 sites
  • Site #203
    Hollywood, Florida 33024, United States
  • Site #201
    South Miami, Florida 33143, United States
  • Site #202
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2015
First posted
Nov 5, 2015
Start
Nov 2015
Primary completionActual
Oct 2016
CompletionActual
Oct 2016
Results delay requested
Oct 12, 2016
Last update
Oct 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02597634
Lead sponsor
Strategic Science & Technologies, LLC
Responsible party
Sponsor
First posted
Nov 5, 2015
Start date
Nov 2015
Primary completion
Oct 2016
Completion
Oct 2016
Last update
Oct 13, 2016

Study contacts

Thomas Wade, MD
principal investigator · Site #201
David Seiden, MD
principal investigator · Site #203
Kayce Morton, DO
principal investigator · Site #202

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion